WuXi Biologics Statistics
Total Valuation
WuXi Biologics has a market cap or net worth of 13.81 billion. The enterprise value is 13.53 billion.
| Market Cap | 13.81B |
| Enterprise Value | 13.53B |
Important Dates
The next estimated earnings date is Wednesday, August 20, 2025.
| Earnings Date | Aug 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -2.80% |
| Shares Change (QoQ) | -1.35% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 3.46B |
Valuation Ratios
The trailing PE ratio is 30.04 and the forward PE ratio is 21.20.
| PE Ratio | 30.04 |
| Forward PE | 21.20 |
| PS Ratio | 5.40 |
| PB Ratio | 2.22 |
| P/TBV Ratio | 2.53 |
| P/FCF Ratio | 78.31 |
| P/OCF Ratio | 19.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.57, with an EV/FCF ratio of 76.68.
| EV / Earnings | 29.42 |
| EV / Sales | 5.34 |
| EV / EBITDA | 16.57 |
| EV / EBIT | 21.76 |
| EV / FCF | 76.68 |
Financial Position
The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.73 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.82 |
| Debt / FCF | 3.84 |
| Interest Coverage | 29.10 |
Financial Efficiency
Return on equity (ROE) is 8.82% and return on invested capital (ROIC) is 5.79%.
| Return on Equity (ROE) | 8.82% |
| Return on Assets (ROA) | 5.05% |
| Return on Invested Capital (ROIC) | 5.79% |
| Return on Capital Employed (ROCE) | 9.48% |
| Revenue Per Employee | 203,466 |
| Profits Per Employee | 36,564 |
| Employee Count | 12,575 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 6.71 |
Taxes
In the past 12 months, WuXi Biologics has paid 121.80 million in taxes.
| Income Tax | 121.80M |
| Effective Tax Rate | 18.39% |
Stock Price Statistics
The stock price has increased by +137.19% in the last 52 weeks. The beta is 0.55, so WuXi Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +137.19% |
| 50-Day Moving Average | 5.89 |
| 200-Day Moving Average | 4.92 |
| Relative Strength Index (RSI) | 62.67 |
| Average Volume (20 Days) | 33,672 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WuXi Biologics had revenue of 2.56 billion and earned 459.79 million in profits. Earnings per share was 0.11.
| Revenue | 2.56B |
| Gross Profit | 1.05B |
| Operating Income | 628.23M |
| Pretax Income | 662.33M |
| Net Income | 459.79M |
| EBITDA | 801.31M |
| EBIT | 628.23M |
| Earnings Per Share (EPS) | 0.11 |
Balance Sheet
The company has 1.47 billion in cash and 676.78 million in debt, giving a net cash position of 790.50 million.
| Cash & Cash Equivalents | 1.47B |
| Total Debt | 676.78M |
| Net Cash | 790.50M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.23B |
| Book Value Per Share | 1.40 |
| Working Capital | 2.05B |
Cash Flow
In the last 12 months, operating cash flow was 714.78 million and capital expenditures -538.37 million, giving a free cash flow of 176.41 million.
| Operating Cash Flow | 714.78M |
| Capital Expenditures | -538.37M |
| Free Cash Flow | 176.41M |
| FCF Per Share | n/a |
Margins
Gross margin is 40.97%, with operating and profit margins of 24.55% and 17.97%.
| Gross Margin | 40.97% |
| Operating Margin | 24.55% |
| Pretax Margin | 25.89% |
| Profit Margin | 17.97% |
| EBITDA Margin | 31.32% |
| EBIT Margin | 24.55% |
| FCF Margin | 6.89% |
Dividends & Yields
WuXi Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.80% |
| Shareholder Yield | n/a |
| Earnings Yield | 3.33% |
| FCF Yield | 1.28% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on December 10, 2020. It was a forward split with a ratio of 3.
| Last Split Date | Dec 10, 2020 |
| Split Type | Forward |
| Split Ratio | 3 |
Scores
WuXi Biologics has an Altman Z-Score of 4.46 and a Piotroski F-Score of 7.
| Altman Z-Score | 4.46 |
| Piotroski F-Score | 7 |